43 related articles for article (PubMed ID: 27723067)
1. The application of CYFRA21-1 in cervical lesions screening in high-risk human papillomavirus infected women.
Yang-Chun F; Jia Y; Yan-Chun H
Ginekol Pol; 2016; 87(9):617-620. PubMed ID: 27723067
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples.
Liu TY; Xie R; Luo L; Reilly KH; He C; Lin YZ; Chen G; Zheng XW; Zhang LL; Wang HB
J Virol Methods; 2014 Feb; 196():120-5. PubMed ID: 24216236
[TBL] [Abstract][Full Text] [Related]
3. [Study on the value assessment of various screening programs regarding cervical cancer screening strategy in the rural areas of China].
Li LY; Qiao ZQ; Zhang MF; Yang JP; Bao YP; An YT; Lei J; Xiong NH; Yu XH; Zhang X; Pan QJ; Qiao YL
Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Oct; 28(10):964-7. PubMed ID: 18399140
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Halfon P; Ruiz F; Smith JS
Int J Cancer; 2011 Aug; 129(3):691-701. PubMed ID: 20941740
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in China.
Xu H; Lin A; Shao X; Shi W; Zhang Y; Yan W
Oncotarget; 2016 Dec; 7(50):83775-83783. PubMed ID: 27626178
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the clinical performance of high-risk human papillomavirus testing for primary screening: a retrospective review of the Southern California Permanente Medical Group experience.
Lonky NM; Mahdavi A; Wolde-Tsadik G; Bajamundi K; Felix JC
J Low Genit Tract Dis; 2010 Jul; 14(3):200-5. PubMed ID: 20592555
[TBL] [Abstract][Full Text] [Related]
7. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
8. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
[TBL] [Abstract][Full Text] [Related]
9. HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway.
Sorbye SW; Fismen S; Gutteberg TJ; Mortensen ES
J Virol Methods; 2010 Oct; 169(1):219-22. PubMed ID: 20638416
[TBL] [Abstract][Full Text] [Related]
10. Can self vaginal douching for high risk HPV screening replace or assist efficacy of cervical cancer screening?
Suwannarurk K; Bhamarapravatana K; Kheolamai P; Thaweekul Y; Mairaing K; Poomtavorn Y; Pattaraarchachai J
Asian Pac J Cancer Prev; 2010; 11(5):1397-401. PubMed ID: 21198300
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study.
Dong L; Wang MZ; Zhao XL; Feng RM; Hu SY; Zhang Q; Smith JS; Qiao YL; Zhao FH
Gynecol Oncol; 2018 Jan; 148(1):103-110. PubMed ID: 29169614
[TBL] [Abstract][Full Text] [Related]
12. Screening for cervical cancer among HIV-positive and HIV-negative women in Cameroon using simultaneous co-testing with careHPV DNA testing and visual inspection enhanced by digital cervicography: Findings of initial screening and one-year follow-up.
Cholli P; Bradford L; Manga S; Nulah K; Kiyang E; Manjuh F; DeGregorio G; Ogembo RK; Orock E; Liu Y; Wamai RG; Sheldon LK; Gona PN; Sando Z; Welty T; Welty E; Ogembo JG
Gynecol Oncol; 2018 Jan; 148(1):118-125. PubMed ID: 29153541
[TBL] [Abstract][Full Text] [Related]
13. Uptake of community-based, self-collected HPV testing vs. visual inspection with acetic acid for cervical cancer screening in Kampala, Uganda: preliminary results of a randomised controlled trial.
Moses E; Pedersen HN; Mitchell SM; Sekikubo M; Mwesigwa D; Singer J; Biryabarema C; Byamugisha JK; Money DM; Ogilvie GS
Trop Med Int Health; 2015 Oct; 20(10):1355-67. PubMed ID: 26031572
[TBL] [Abstract][Full Text] [Related]
14. [The impact of natural history and genital tract distribution of human papillomavirus on technology for cervical cancer screening].
Wu ZN; Chen W
Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):241-5. PubMed ID: 27087368
[TBL] [Abstract][Full Text] [Related]
15. Serum CYFRA21-1 and SCC-Ag levels in women during pregnancy and their diagnostic value for cervical cancer.
Zhang Q; Wang Z; Tang H; Zhang B; Yue C; Gao J; Ying C
Cancer Treat Res Commun; 2024; 38():100786. PubMed ID: 38198984
[TBL] [Abstract][Full Text] [Related]
16. The current status of cell-free human papillomavirus DNA as a biomarker in cervical cancer and other HPV-associated tumors: A review.
Sivars L; Palsdottir K; Crona Guterstam Y; Falconer H; Hellman K; Tham E
Int J Cancer; 2023 Jun; 152(11):2232-2242. PubMed ID: 36274628
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive bioassay of Cytokeratin Fragment 21.1 (Cyfra 21.1) protein in human saliva samples using immunoreaction method: An efficient platform for early-stage diagnosis of oral cancer based on biomedicine.
Jafari M; Hasanzadeh M
Biomed Pharmacother; 2020 Nov; 131():110671. PubMed ID: 32853907
[TBL] [Abstract][Full Text] [Related]
18. Electrochemiluminescent immunoassay for the lung cancer biomarker CYFRA21-1 using MoO
Meng X; Chen X; Wu W; Zheng W; Deng H; Xu L; Chen W; Li Z; Peng H
Mikrochim Acta; 2019 Nov; 186(12):855. PubMed ID: 31784817
[TBL] [Abstract][Full Text] [Related]
19. CYFRA21-1/TG ratio as an accurate risk factor to predict eye metastasis in nasopharyngeal carcinoma: A STROBE-compliant article.
Peng SJ; Wang CF; Yu YJ; Yu CY; Chen SY; Wu SN; Tan SW; Peng JX; Li B; Shao Y
Medicine (Baltimore); 2020 Nov; 99(46):e22773. PubMed ID: 33181649
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Value of Dynamic Enhanced Magnetic Resonance Imaging Combined with Serum CA15-3, CYFRA21-1, and TFF1 for Breast Cancer.
Xue F; Meng Y; Jiang J
J Healthc Eng; 2022; 2022():7984591. PubMed ID: 35392152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
